Luna wins NIH grant to use nanotechnology for allergy treatment

This novel research program may offer a new therapeutic solution using fullerene compounds for treating allergies and other conditions that play a central role in inflammatory reactions, such as arthritis and multiple sclerosis. The study will include evaluating Luna’s exclusive nanomedicine prototypes.

In this program under the National Institutes of Health’s (NIH) National Institute of General Medical Sciences, Luna will explore whether fullerenes control allergies by investigating the systemic, cellular and molecular responses in vivo and in vitro.

Chris Kepley, nanoimmunology group leader at Luna, said: “We have discovered that our fullerene prototypes block the noxious effects of allergies and therefore may be a new way to control allergies and other diseases that are largely due to mast cell and basophil responses.”